

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH AN  
**OVERACTIVE BLADDER**

1. Lightner DJ, Gomelsky A, Souter L, Vasavada SP: **Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019.** *J Urol* 2019, **202**(3):558-563.
2. Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C, Radomski SB, Stothers L, Wagg A, Lond F: **CUA guideline on adult overactive bladder.** *Can Urol Assoc J* 2017, **11**(5):E142-e173.
3. Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, Tubaro A: **EAU Guidelines on Urinary Incontinence in Adults.** In: *European Association of Urology.* 2020.
4. Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS: **Updating the evidence on drugs to treat overactive bladder: a systematic review.** *Int Urogynecol J* 2019, **30**(10):1603-1617.
5. Makhani A, Thake M, Gibson W: **Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.** *Clin Interv Aging* 2020, **15**:575-581.
6. Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, Glanville JM, Fleetwood K, James D, Chapple CR: **Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.** *BJU Int* 2017, **120**(5):611-622.
7. Geoffrion R: **Treatments for overactive bladder: focus on pharmacotherapy.** *J Obstet Gynaecol Can* 2012, **34**(11):1092-1101.
8. National Institute for Health and Care Excellence: **Urinary incontinence and pelvic organ prolapse in women: management [NICE Guideline NG123].** In: *NICE Guideline.* 2019.
9. National Institute for Health and Care Excellence: **Lower urinary tract symptoms in men: management [NICE Guideline CG97].** In: *NICE Guideline.* 2010.
10. Davila GW, Martin L: **Urinary incontinence in women.** In: *BMJ Best Practice.* 2020.
11. Mulherin K, Regier L, Jensen B: **Urinary Incontinence: Drug Comparison Chart.** In: *RxFiles Drug Comparison Charts.* vol. 12th ed. Saskatoon, SK: Saskatoon Health Region 2019: 75-76.
12. National Institute for Health and Care Excellence: **Urinary incontinence in women: the management of urinary incontinence in women [NICE Full NG123] - Full version.** In: *NICE Guideline.* 2013.
13. Geoffrion R: **No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.** *J Obstet Gynaecol Can* 2017, **39**(12):1221-1229.
14. Geoffrion R: **No. 283-Treatments for Overactive Bladder: Focus on Pharmacotherapy.** *J Obstet Gynaecol Can* 2018, **40**(1):e22-e32.
15. Balk EM, Rofeberg VN, Adam GP, Kimmel HJ, Trikalinos TA, Jeppson PC: **Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women: A**

- Systematic Review and Network Meta-analysis of Clinical Outcomes.** *Ann Intern Med* 2019, **170**(7):465-479.
16. Lozano-Ortega G, Walker DR, Johnston K, Mickle A, Harrigan S, Rogula B, Kristy RM, Hairston JC, Schermer CR: **Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.** *Drugs Aging* 2020, **37**(11):801-816.
  17. Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF: **Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.** *Arch Gerontol Geriatr* 2017, **69**:77-96.
  18. Kessler TM, Bachmann LM, Minder C, Löhner D, Umbehrl M, Schünemann HJ, Kessels AG: **Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.** *PLoS One* 2011, **6**(2):e16718.
  19. Hu JS, Pierre EF: **Urinary Incontinence in Women: Evaluation and Management.** *Am Fam Physician* 2019, **100**(6):339-348.
  20. Arnold J, McLeod N, Thani-Gasalam R, Rashid P: **Overactive bladder syndrome - management and treatment options.** *Aust Fam Physician* 2012, **41**(11):878-883.
  21. Searchlight Pharma Inc.: **Enablex (darifenacin extended release).** In: *CA Product Monograph.* Montreal, QC; 2019.
  22. Cipla USA Inc.: **Darifenacin extended release.** In: *US Product Monograph.* Warren, NJ; 2020.
  23. Pfizer Canada Inc.: **Toviaz (fesoterodine extended-release).** In: *CA Product Monograph.* Kirkland, QC; 2017.
  24. Pfizer Labs: **Toviaz (fesoterodine extended-release).** In: *US Product Monograph.* New York, NY; 2017.
  25. Astellas Pharma Canada Inc.: **Myrbetriq (mirabegron extended-release).** In: *CA Product Monograph.* Markham, ON; 2016.
  26. Astellas Pharma US Inc.: **Myrbetriq (mirabegron extended release).** In: *US Product Monograph.* Northbrook, IL; 2019.
  27. Laboratoire Riva Inc.: **Oxybutynin tablets.** In: *CA Product Monograph.* Blainville, QC; 2016.
  28. Janssen Inc.: **Ditropan XL (oxybutynin extended-release).** In: *CA Product Monograph.* Toronto, ON; 2019.
  29. Allergan Inc.: **Oxytrol (oxybutynin transdermal system).** In: *CA Product Monograph.* Markham, ON; 2018.
  30. Eywa Pharma Inc.: **Oxybutynin tablet.** In: *US Product Monograph.* Princeton, NJ; 2019.
  31. Janssen Pharmaceuticals Inc.: **Ditropan XL (oxybutynin extended release).** In: *US Product Monograph.* Titusville, NJ; 2019.
  32. Allergan USA Inc.: **Oxytrol (oxybutynin transdermal system).** In: *US Product Monograph.* Irvine, CA; 2017.
  33. Allergan USA Inc.: **Gelnique (oxybutynin gel).** In: *US Product Monograph.* Irvine, CA; 2017.
  34. Duchesnay Inc.: **Mictoryl (propiverine).** In: *CA Product Monograph.* Blainville, QC; 2018.
  35. Auro Pharma Inc.: **Solifenacin.** In: *CA Product Monograph.* Woodbridge, ON; 2019.

36. Astellas Pharma US Inc.: **Vesicare (solifenacin)**. In: *US Product Monograph*. Northbrook, IL; 2020.
37. Upjohn Canada ULC: **Detrol (tolterodine)**. In: *CA Product Monograph*. Kirkland, QC; 2020.
38. Upjohn Canada ULC: **Detrol LA (tolterodine extended release)**. In: *CA Product Monograph*. Kirkland, QC; 2020.
39. Rising Pharma Holdings Inc.: **Tolterodine**. In: *US Product Monograph*. East Brunswick, NJ; 2020.
40. PD-Rx Pharmaceuticals Inc.: **Detrol LA (tolterodine extended release)**. In: *US Product Monograph*. Oklahoma City, OK; 2019.
41. Sunovion Pharmaceuticals Canada Inc.: **Trosec (trospium)**. In: *CA Product Monograph*. Mississauga, ON; 2019.
42. Cipla USA Inc.: **Trospium**. In: *US Product Monograph*. Warren, NJ; 2020.
43. BluePoint Laboratories: **Trospium extended release**. In: *US Product Monograph*. Chantilly, VA; 2020.
44. Urovant Sciences Inc.: **Gemtesa (vibegron)**. In: *US Product Monograph*. Irvine, CA; 2020.
45. Allergan Inc.: **Botox (onabotulinumtoxinA for injection)**. In: *CA Product Monograph*. Markham, ON; 2018.
46. Allergan USA Inc.: **Botox (onabotulinumtoxinA for injection)**. In: *US Product Monograph*. Madison, NJ; 2020.
47. Pfizer Canada Inc.: **Premarin Vaginal Cream (conjugated estrogens)**. In: *CA Product Monograph*. Kirkland, QC; 2018.
48. Novo Nordisk Canada Inc.: **Vagifem 10 (estradiol vaginal tablets with applicators)**. In: *CA Product Monograph*. Mississauga, ON; 2016.
49. Pfizer Canada Inc.: **Estring (estradiol vaginal ring)**. In: *CA Product Monograph*. Kirkland, QC; 2017.
50. Wyeth Pharmaceuticals Inc.: **Premarin Vaginal Cream (conjugated estrogens)**. In: *US Product Monograph*. Philadelphia, PA; 2017.
51. Novo Nordisk Inc.: **Vagifem (estradiol vaginal inserts)**. In: *US Product Monograph*. Plainsboro, NJ; 2019.
52. Pharmacia & Upjohn Co.: **Estring (estradiol vaginal ring)**. In: *US Product Monograph*. New York, NY; 2015.
53. US Food and Drug Association: **Table of Pharmacogenetic Associations**. In: <https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations>. 2020.
54. Kerbusch T, Wahlby U, Milligan PA, Karlsson MO: **Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability**. *Br J Clin Pharmacol* 2003, **56**(6):639-652.
55. Malhotra B, Darsey E, Crownover P, Fang J, Glue P: **Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers**. *Br J Clin Pharmacol* 2011, **72**(2):226-234.
56. Malhotra B, Guan Z, Wood N, Gandelman K: **Pharmacokinetic profile of fesoterodine**. *Int J Clin Pharmacol Ther* 2008, **46**(11):556-563.

57. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S *et al*: **Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist.** *Clin Drug Investig* 2013, **33**(6):429-440.
58. Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J: **Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.** *Clin Pharmacol Ther* 1998, **63**(5):529-539.
59. Brynne N, Bottiger Y, Hallen B, Bertilsson L: **Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.** *Br J Clin Pharmacol* 1999, **47**(2):145-150.
60. Brynne N, Svanstrom C, Aberg-Wistedt A, Hallen B, Bertilsson L: **Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.** *Br J Clin Pharmacol* 1999, **48**(4):553-563.
61. Oishi M, Chiba K, Malhotra B, Suwa T: **Effect of the CYP2D6\*10 genotype on tolterodine pharmacokinetics.** *Drug Metab Dispos* 2010, **38**(9):1456-1463.
62. Olshansky B, Serra DB: **Thorough QT study with recommended and supratherapeutic doses of tolterodine.** *Clin Pharmacol Ther* 2008, **83**(2):231-232; author reply 233.